July 28, 2016
Listed exchanges : Tokyo
Listed company name: Kobayashi Pharmaceutical Co., Ltd. Code : 4967
URL : http://www.kobayashi.co.jp/ Representative officer: Akihiro Kobayashi, President & COO Contact : Satoshi Yamane,
Senior Executive Director & Senior General Manager, Corporate Administration Headquarters
Tel : +81-6-6222-0142
Expected date for submitting quarterly securities report : August 9, 2016 Preparation of supplementary explanation documents for quarterly financial results : None
Holding of an analyst meeting for quarterly financial results : None
(Any fraction less than 1 million yen is rounded down to the nearest million yen.)
1. Consolidated Results for 1st Quarter of Fiscal Year Ending December 31, 2016 (April 1, 2016 to June 30, 2016)(1) Consolidated Operating Results (accumulation)
(% figures represent changes from same period in previous year)
Q1 of FY ending December 31, 2016 Q1 of FY ended March 31, 2016
Net sales | 36,767 | millions of yen | % | 29,971 | millions of yen | 10.3 | % |
Operating income | 7,299 | | 4,453 | 33.8 | |||
Ordinary income | 7,142 | | 4,632 | 28.6 | |||
Net income attributable to owners of the parent | 5,219 | | 2,884 | 19.3 | |||
Net income per share | 64.97 | yen | 35.43 | yen | |||
Net income per share after full dilution | 64.92 | |
(Note) Comprehensive income: Q1 of FY ending December 31, 2016: 1,243 million yen (%)
Q1 of FY ended March 31, 2016 : 4,874 million yen (192.6%)
Following the approval of the proposal "Partial Amendment to the Articles of Incorporation" at the 98th Ordinary General Meeting of Shareholders held on June 29, 2016, the Company changed the book-closing date from March 31 to December 31, effective from FY 2016. Accordingly, the current consolidated fiscal year is a transitional period for the change in accounting period, meaning an irregular period, in which the consolidated operating results cover three months (April 1, 2016 to June 30, 2016) for the Company and its consolidated subsidiaries that close their accounts in March, as opposed to six months (January 1, 2016 to June 30, 2016) for consolidated subsidiaries that close their accounts in December. Therefore, the percentage of year-on-year changes has been omitted in the tables above.
The Company implemented a two-for-one common stock split effective July 1, 2016. Net income per share and net income per share after full dilution were calculated on the assumption that the relevant stock split had been implemented at the beginning of the previous consolidated fiscal year.
Q1 of FY ending December 31, 2016 | As of March 31, 2016 | |||
Total assets | 188,754 | millions of yen | 188,997 | millions of yen |
Net assets | 141,378 | 142,023 | ||
Shareholders' equity ratio | 74.8 | % | 75.1 | % |
Net assets per share | 1,758.24 | yen | 1,766.06 | yen |
(Reference) Shareholders' equity
Q1 of FY ending December 31, 2016: 141,257 million yen As of March 31, 2016: 141,873 million yen
The Company implemented a two-for-one common stock split effective July 1, 2016. Net assets per share were calculated on the assumption that the relevant stock split had been implemented at the beginning of the previous consolidated fiscal year.
2. Dividends
Year ended March 2016 | FY ending December 2016 | FY ending December 2016 (forecasts) | |||
Dividends per share | |||||
Q1 end | | | |||
Q2 end | 48.00 | yen | 24.00 | yen | |
Q3 end | | | |||
Year-end | 48.00 | 24.00 | |||
Total | 96.00 | 48.00 |
(Note) Revision of the latest dividend forecast: None
The Company implemented a two-for-one common stock split effective July 1, 2016. The Q2-end and year-end dividends per share for the consolidated fiscal year ending December 31, 2016 (forecast) are stated taking into consideration the relevant stock split.
3. Forecasts of Consolidated Operational Results for Fiscal Year Ending December 31, 2016 (April 1, 2016 to December 31, 2016)(% figures represent changes from same period in previous year) 6-month period ending September 30, 2016
(accumulation) FY ending December 31, 2016
Net sales | 73,000 | millions of yen | % | 117,300 | millions of yen | % |
Operating income | 10,600 | | 16,900 | | ||
Ordinary income | 10,600 | | 18,800 | | ||
Net income attributable to | 7,000 | | 13,500 | | ||
owners of the parent | ||||||
Earnings per share | 87.13 | yen | 168.04 | yen |
(Note) Revision of the latest forecasts of operational results: Yes
Following the approval of the proposal "Partial Amendment to the Articles of Incorporation" at the 98th Ordinary General Meeting of Shareholders held on June 29, 2016, the Company changed the book-closing date from March 31 to December 31, effective from FY 2016. Accordingly, the consolidated fiscal year ending December 31, 2016 is a transitional period for the change in accounting period, covering nine months (April 1, 2016 to December 31, 2016) for the Company and its consolidated subsidiaries that close their accounts in March. The consolidated accounting period for the consolidated subsidiaries that close their accounts in December covers 12 months (January 1, 2016 to December 31, 2016) as in the previous year.
[Reference]
Net sales
Operating income
Ordinary income
Net income attributable to owners of the parent
(Millions of yen)
117,300
4.3%
16,900
(1.9%)
18,800
10.0%
13,500
5.8%
The percentages shown below (adjusted changes) represent ratios of change by comparing the nine-month results for the previous fiscal year for the Company and its consolidated subsidiaries that close their accounts in March (April 1, 2015 to December 31, 2015) and 12-month results for the previous fiscal year for the consolidated subsidiaries that close their accounts in December (January 1, 2015 to December 31, 2015) with the full-year forecasts for the fiscal year ending December 31, 2016.
The Company implemented a two-for-one common stock split effective July 1, 2016. Net income per share for the first six-month period and the full-year for the consolidated fiscal year ending December 31, 2016 is stated taking into consideration the relevant stock split.
* Notes
Changes in significant subsidiaries during the period (Changes in specified subsidiaries accompanying changes of the scope of consolidation): None
Newly consolidated: - (company name: ), Eliminated from the scope of consolidation: - (company name: )
Adoption of special accounting methods for preparing quarterly consolidated financial statements: None
Changes in accounting policies, changes in accounting estimates and retrospective restatement
Changes in accounting policies due to revisions of accounting standards: None
Changes of accounting policies other than the above: None
Changes in accounting estimates: None
Retrospective restatement: None
Q1 of FY ending December 31, 2016
85,050,000
shares
FY ended March 31, 2016
85,050,000
shares
Q1 of FY ending December 31, 2016
4,709,426
shares
FY ended March 31, 2016
4,716,626
shares
Q1 of FY ending December 31, 2016
80,335,996
shares
Q1 of FY ended March 31, 2016
81,434,432
shares
Issued shares (common shares)
Number of shares issued at period-end (including treasury stock):
Number of shares of treasury stock at period-end
Average number of shares outstanding during period (consolidated cumulative quarters)
The Company implemented a two-for-one common stock split effective July 1, 2016. Number of issued shares (common shares) was calculated on the assumption that the relevant stock split had been implemented at the beginning of the previous consolidated fiscal year.
Information on implementation of quarterly review procedures
This brief report of quarterly financial statements is not subject to audit procedures under the Financial Instruments and Exchange Act. Audit procedures concerning quarterly financial statements have not been completed under the Financial Instruments and Exchange Act at the date of disclosure of this brief report of quarterly financial statements.
Explanation on appropriate use of forecasts of business results and other special items
The forward-looking statements in this document concerning forecasting of operational results, etc. are based on currently available information and assumptions considered reasonable by the Company. Actual operational results may be significantly different from these statements due to various factors. For the assumptions used as the basis for forecasts of operational results and important matters when using the forecast of performance, please refer to "1. Qualitative Information on Quarterly Results, (3) Explanation of future forecast information, such as forecast of consolidated results" on page 4 of the attachment.
Kobayashi Pharmaceutical Co., Ltd. (4967)
Summary of Financial Statements 1st Quarter of the Fiscal Year Ending December 31, 2016
Table of Contents for Attachment
Qualitative Information on Quarterly Results 2
Explanation of operational results 2
Explanation of financial position 3
Explanation of future forecast information, such as forecast of consolidated results 4
Matters concerning Summary Information (Notes) 4
Changes in significant subsidiaries during the period 4
Adoption of special accounting methods for preparing quarterly consolidated financial statements 4
Changes in accounting policies 4
Additional information 4
Quarterly Financial Statements 5
Consolidated quarterly balance sheet 5
Consolidated quarterly statements of income and consolidated quarterly statements of comprehensive income 7
Consolidated quarterly statements of income
Three-month period ended June 30, 2016 7
Consolidated quarterly statements of comprehensive income
Three-month period ended June 30, 2016 8
Notes on quarterly consolidated financial statements 9
(Notes on assumption of going concern) 9
(Notes on a significant change in shareholders' equity) 9
(Segment information, etc.) 9
(Significant subsequent events) 10
- 1 -
Kobayashi Pharmaceutical Co. Ltd. published this content on 28 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 August 2016 01:07:10 UTC.
Original documenthttp://www.kobayashi.co.jp/english/ir/results/pdf/2017_01.pdf
Public permalinkhttp://www.publicnow.com/view/B8A5215AB4D539CDE29B1323C4446A79C3020748